Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.

World neurosurgery - 1 Dec 2023

Wu Ze-Pei, Wang Yue-Long, Wang Li-Chong, Liu Zhi-Yong, Fan Rang-Rang, Zan Xin, Liang Rui-Chao, Yang Jin-Long, Zhou Liang-Xue, Xu Jian-Guo

Abstract excerpt

BACKGROUND: Although a benign intracranial tumor, craniopharyngioma treatment has always been considered a challenging clinical problem. Recently, BRAF V600E mutation in the pathogenesis of papillary craniopharyngioma (PCP) has been further revealed. Thus, BRAF inhibitors (BRAFi) serve as an applicable treatment for patients with PCP. METHODS: Two patients with recurrent PCP were treated with combined BRAFi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Craniopharyngioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Pituitary Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 37683921
DOI: 10.1016/j.wneu.2023.08.137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.PMID 37683921Read ↗

Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.Semantic proximity Read ↗

Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.Semantic proximity Read ↗

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.Semantic proximity Read ↗

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.Semantic proximity Read ↗

Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.Semantic proximity Read ↗

BRAF plus MEK inhibition effective in papillary craniopharyngioma.Semantic proximity Read ↗

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.Semantic proximity Read ↗

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutationsSemantic proximity Read ↗

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.Semantic proximity Read ↗

Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma.Semantic proximity Read ↗

[Molecularly Targeted Therapy for Craniopharyngioma].Semantic proximity Read ↗

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngiomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.